The Life Sciences Law Firm Index: Patent Category Update
Which law firms were at the top of our patent category through Q3 2017?
Wilson Sonsini Tops Life Sciences Law Firm Index For 2nd Straight Year
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
What You Didn’t Learn In Law School
How do you keep up with the competition? Share your perspective in this brief survey to help us benchmark your lifelong training in professional skills. As a thank you, qualified respondents receive a chance to win a $250 gift card.
Finding A Way Through A Tight Deal Space
Leaders of WilmerHale’s life sciences practice share trends they see regarding acquisitions and initial public offerings.
Navigating The Life Science M&A Savannah
What does the market for life sciences M&A look like right now?
Collaboration At Fenwick & West Steers Firm Through Complex Deals
What does the market for life sciences companies look like right now?
Newly United Arnold & Porter Kaye Scholer Surveys Changed Life Sciences Deal Environment
Experts offer their takes on the developing dealmaking environment in the early days of the Trump Administration.
Managing Partners are Navigating the AI Inflection Point.
New executive research from Ari Kaplan explores how law firm leaders are responding to changing client expectations, evolving economics, talent transformation, and AI governance.
The Life Sciences Law Firm Index: Patent Category Update
Which law firms were at the top of our patent category through Q1 2016?
Aggregate Spend Goes Global
As states began to jump onto the pharmaceutical regulation bandwagon around the turn of the century, Porzio Bromberg & Newman brought John Ohoro on to help clients sift through the growing maze of rules and regulations across the U.S.
Friends And Family (Offices) Step In To Funding Drought
Not too long ago, it didn’t take much for someone with an idea for a new medical device to rake in the early-stage funding.
M&A: The Last Refuge For Biotechs Seeking Funding
These are tough times in the biotech and pharmaceutical industries: Funding is drying up, investors are fleeing the space, the IPO door is pretty firmly shut, valuations are dropping, activists are lurking and the headlines are anything but kind. But when the going gets tough, the tough consider strategic alternatives...
Why Experience Still Matters In An AI-Driven Legal Industry
A conversation with Trustpoint.One CEO Christopher Gallagher.